Using PD-L1 as a Biomarker of Response
Michael A. Postow, MD, attending physician, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, discusses using PD-L1 as a biomarker of response in melanoma.
Clinical Pearls
Michael A. Postow, MD, attending physician, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, discusses using PD-L1 as a biomarker of response in melanoma.
- There remains a need to determine the utility of PD-L1 as a biomarker of response to PD-1-inhibiting agents.
- Patients with high levels of PD-L1 within their tumor are more likely to respond to PD-1-inhibiting agents.
- Patients that do not express PD-L1 can still benefit from PD-1 blockade.
- Regardless of PD-L1 status, patients will be given the option of being treated with PD-1-inhibiting agents until more data are available.
Recent Videos
Related Content
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024Article
In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
